Mdxhealth, Inc. (MDXH)

They are a commercial-stage precision diagnostics company committed to providing non-invasive, clinically actionable and cost-effective urologic solutions to improve patient care. Their novel prostate cancer genomic testing solutions, SelectMDx and ConfirmMDx, provide physicians with a clear clinical pathway to accurately identify clinically significant prostate cancer while minimizing the use of invasive procedures that are prone to complications. Their unique approach combines advanced clinical modeling with genomic data to provide each patient with a personalized cancer risk profile, which provides more accurate and actionable information than standard risk factors (e.g., Prostate Specific Antigen (“PSA”), digital rectal exam (“DRE”), age) used by clinicians. Their lead products address men at risk for developing prostate cancer, but in addition, they are actively developing testing solutions to help with the management of men diagnosed with prostate cancer, with the goal to provide their clients with a menu of tools spanning the continuum of prostate cancer diagnosis and care. Their expertise in precision diagnostics and their portfolio of novel biomarkers for diagnostic, prognostic and predictive molecular assays supports their active pipeline of new testing solutions for prostate and other urologic diseases.

What do you think will happen with the GLSI share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)